Novartis and travel-guide guru publish free bathroom book

Share this article:

Novartis is partnering with travel guide guru Arthur Frommer to publish Where to Stop and Where to Go: A Guide to Traveling with Overactive Bladder in the United States.The 75-page guide covers key attractions in 19 U.S. cities and four national parks, with an eye toward restroom locations, and will be distributed free-of-charge through the book's Web site, www.heretostopwheretogo.com.
Though the book's colors are aligned with the branding of Novartis' Overactive Bladder drug Enablex, the book itself does not include explicit references to the brand. Visitors to the Web site who opt in for mailings will receive information on the drug. Relationship marketing for the campaign is handled by Cary, N.C.-based MicroMass Communications, while Ketchum Healthcare is shopping Frommer around consumer news media. The book debuted at the annual meeting of the American Urological Association in San Antonio last month where Frommer manned a company booth, and literature will be distributed through specialists' offices over the course of the coming weeks.

 

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...